Jci_page_head_homepage_01 Jci_page_head_homepage_02
Tony Hunter
Published in Volume 117, Issue 8
J Clin Invest. 2007; 117(8):2036–2043 doi:10.1172/JCI31691
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1
A timeline of the different avenues of research endeavor that came together and led to the successful development of imatinib as a treatment for CML.

Most of these disparate research efforts were started through a desire to understand the mechanisms underlying cancer and to ultimately develop therapies. A significant acceleration in progress came in the 1970s with Nixon’s “war on cancer,” which brought a lot of new people and ideas into the cancer field. The advent of molecular cloning and DNA sequencing in the mid-1970s also played a critical role, allowing for the identification of oncogenes and their products. gof, gain-of-function; HZ4-FeSV, Hardy-Zuckerman 4 feline sarcoma virus; mT, middle T antigen; NEJM, New England Journal of Medicine; Ph chr, Philadelphia chromosome; PK, protein kinase; TK, tyrosine kinase; TKI, tyrosine kinase inhibitor.